International research networks in pediatric rheumatology: the PRINTO perspective

Nicolino Ruperto1, Alberto Martini

  • 1IRCCS G. Gaslini, Università di Genova, Pediatria II-Reumatologia, Genova, Italy. nicolaruperto@ospedale-gaslini.ge.it

Insights

International research networks like PRINTO and PRCSG address challenges in pediatric rheumatic diseases research. Standardized measures and validated instruments improve treatment assessments for children.

Area of Science:

  • Rheumatology
  • Pediatric Research
  • Clinical Trials

Background:

  • Pediatric rheumatic diseases are rare, impacting quality of life and long-term outcomes.
  • Researching new therapies faces logistic, methodological, and ethical hurdles.
  • International collaboration is crucial for advancing pediatric rheumatology.

Purpose of the Study:

  • To identify challenges in international collaborative research for pediatric rheumatic diseases.
  • To present solutions and successful models for conducting such research.
  • To highlight the importance of networks in pediatric rheumatology research.

Main Methods:

  • Establishment of international networks: Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology international Trials Organization (PRINTO).
  • Development and standardization of outcome measures and response criteria.
  • Cross-cultural adaptation and validation of quality-of-life instruments.

Main Results:

  • Standardized evaluation of therapeutic response in juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, and juvenile dermatomyositis.
  • Defined clinical remission criteria for juvenile idiopathic arthritis.
  • Validated quality-of-life instruments (e.g., Childhood Health Assessment Questionnaire) in 32 languages.

Conclusions:

  • International trial networks (PRINTO, PRCSG) are essential for pediatric rheumatic diseases research.
  • Standardized outcome measures and validated instruments enhance assessment quality.
  • Progress enables children to benefit from evidence-based treatments comparable to adults.
Abstract